$307 Million is the total value of Opaleye Management Inc.'s 41 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 48.9% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| HROW | Buy | HARROW HEALTH INC | $54,534,150 | -24.1% | 3,795,000 | +0.5% | 17.74% | +3.2% |
| Sell | ACELYRIN INC | $42,166,223 | -51.5% | 4,146,138 | -0.3% | 13.72% | -34.0% | |
| OCUL | Buy | OCULAR THERAPEUTIX INC | $20,309,520 | -31.9% | 6,468,000 | +11.9% | 6.61% | -7.4% |
| TGTX | New | TG THERAPEUTICS INC | $15,800,400 | – | 1,890,000 | +100.0% | 5.14% | – |
| RYTM | Sell | RHYTHM PHARMACEUTICALS INC | $14,970,025 | +23.5% | 653,000 | -11.2% | 4.87% | +68.0% |
| CPRX | New | CATALYST PHARMACEUTICALS INC | $14,086,450 | – | 1,205,000 | +100.0% | 4.58% | – |
| KROS | Buy | KEROS THERAPEUTICS INC | $11,489,552 | -18.9% | 360,400 | +2.2% | 3.74% | +10.3% |
| Sell | BIOHAVEN LTD | $11,418,390 | -11.6% | 439,000 | -18.7% | 3.72% | +20.2% | |
| CRNX | Sell | CRINETICS PHARMACEUTICALS INC | $11,003,800 | -27.7% | 370,000 | -56.2% | 3.58% | -1.7% |
| ETON | Buy | ETON PHARMACEUTICALS INC | $10,134,226 | +27.1% | 2,430,270 | +6.4% | 3.30% | +72.8% |
| IDYA | Sell | IDEAYA BIOSCIENCES INC | $8,404,270 | -13.8% | 311,500 | -24.9% | 2.73% | +17.2% |
| MOR | MORPHOSYS AGsponsored ads | $8,127,034 | -10.0% | 1,209,380 | 0.0% | 2.64% | +22.4% | |
| TELA | Sell | TELA BIO INC | $6,000,000 | -62.5% | 750,000 | -52.5% | 1.95% | -49.0% |
| EWTX | Buy | EDGEWISE THERAPEUTICS INC | $5,016,071 | -20.6% | 875,405 | +7.4% | 1.63% | +8.0% |
| KALV | Sell | KALVISTA PHARMACEUTICALS INC | $4,815,000 | -25.7% | 500,000 | -30.6% | 1.57% | +1.0% |
| Sell | MARINUS PHARMACEUTICALS INC | $4,701,200 | -30.7% | 584,000 | -6.6% | 1.53% | -5.8% | |
| PCVX | Sell | VAXCYTE INC | $4,588,200 | -48.1% | 90,000 | -49.2% | 1.49% | -29.4% |
| TARA | PROTARA THERAPEUTICS INC | $4,496,632 | -30.1% | 2,692,594 | 0.0% | 1.46% | -4.9% | |
| URGN | Sell | UROGEN PHARMA LTD | $4,483,200 | -24.0% | 320,000 | -43.9% | 1.46% | +3.4% |
| GERN | Sell | GERON CORP | $4,059,800 | -46.2% | 1,915,000 | -18.5% | 1.32% | -26.8% |
| GOSS | Buy | GOSSAMER BIO INC | $3,959,298 | -2.1% | 4,754,200 | +41.1% | 1.29% | +33.2% |
| FDMT | Buy | 4D MOLECULAR THERAPEUTICS INC | $3,927,205 | -2.0% | 308,500 | +39.2% | 1.28% | +33.4% |
| XOMA | Sell | XOMA CORP DEL | $3,867,705 | +550.3% | 274,500 | -0.2% | 1.26% | +785.9% |
| TRVI | Buy | TREVI THERAPEUTICS INC | $3,718,862 | -8.6% | 1,705,900 | +0.3% | 1.21% | +24.4% |
| LQDA | LIQUIDIA CORPORATION | $3,618,238 | -19.2% | 570,700 | 0.0% | 1.18% | +9.8% | |
| LRMR | Sell | LARIMAR THERAPEUTICS INC | $3,351,575 | -23.0% | 848,500 | -39.0% | 1.09% | +4.7% |
| Sell | NYXOAH S A | $3,115,367 | -12.6% | 441,896 | -0.7% | 1.01% | +18.9% | |
| New | GOSSAMER BIO INCnote 5.000% 6/0 | $3,098,704 | – | 8,000,000 | +100.0% | 1.01% | – | |
| BDSX | New | BRIDGEBIO PHARMA INC | $3,038,295 | – | 455,573 | +100.0% | 0.99% | – |
| IOVA | Buy | IOVANCE BIOTHERAPEUTICS INC | $2,775,500 | -6.4% | 610,000 | +44.9% | 0.90% | +27.4% |
| APLT | New | APPLIED THERAPEUTICS | $2,223,570 | – | 893,000 | +100.0% | 0.72% | – |
| IGMS | Buy | IGM BIOSCIIENCES INC | $2,179,350 | +271.8% | 261,000 | +311.0% | 0.71% | +406.4% |
| CDXS | Buy | CODEXIS INC | $2,114,721 | +11.9% | 1,118,900 | +65.8% | 0.69% | +52.2% |
| Buy | VERASTEM INC | $1,718,682 | +126.5% | 211,400 | +107.3% | 0.56% | +207.1% | |
| PGEN | New | PRECIGEN INC | $1,318,470 | – | 928,500 | +100.0% | 0.43% | – |
| TCON | TRACON PHARMACEUTICALS INC | $848,082 | -38.8% | 4,764,508 | 0.0% | 0.28% | -16.9% | |
| New | XERIS BIOPHARMA HOLDINGS INC | $725,400 | – | 390,000 | +100.0% | 0.24% | – | |
| FBIO | Sell | FORTRESS BIOTECH INC | $580,600 | -68.1% | 2,000,000 | -39.6% | 0.19% | -56.6% |
| KZR | Buy | KEZAR LIFE SCIENCES INC | $505,750 | +108.9% | 425,000 | +330.2% | 0.16% | +184.5% |
| RLMD | New | RELMADA THERAPEUTICS INC | $90,000 | – | 30,000 | +100.0% | 0.03% | – |
| FULC | Exit | FULCRUM THERAPEUTICS INC | $0 | – | -143,600 | -100.0% | -0.11% | – |
| JNCE | Exit | JASPER | $0 | – | -669,944 | -100.0% | -0.22% | – |
| PRQR | Exit | PROQR THERAPEUTICS NV | $0 | – | -653,000 | -100.0% | -0.25% | – |
| BDTX | Exit | BLACK DIAMOND THERAPEUTICS | $0 | – | -275,000 | -100.0% | -0.33% | – |
| STRO | Exit | SUTRO BIOPHARMA INC | $0 | – | -307,000 | -100.0% | -0.34% | – |
| Exit | ASTRIA THERAPEUTICS INC | $0 | – | -305,000 | -100.0% | -0.61% | – | |
| STXS | Exit | SPECTRUM PHARMACEUTICALS | $0 | – | -3,074,995 | -100.0% | -0.71% | – |
| KPTI | Exit | KARYOPHARM THERAPEUTICS INC | $0 | – | -1,785,000 | -100.0% | -0.76% | – |
| EDAP | Exit | EDAP TMS S Asponsored adr | $0 | – | -380,000 | -100.0% | -0.84% | – |
| CYTK | Exit | CYTOKINETICS INC | $0 | – | -130,000 | -100.0% | -1.01% | – |
| NTLA | Exit | INTELLIA THERAPEUTICS INC | $0 | – | -120,000 | -100.0% | -1.17% | – |
| ACAD | Exit | ACADIA PHARMACEUTICALS INC | $0 | – | -217,000 | -100.0% | -1.24% | – |
| Exit | THESEUS PHARMACEUTICALS INC | $0 | – | -597,500 | -100.0% | -1.33% | – | |
| TBPH | Exit | THERAVANCE BIOPHARMA INC | $0 | – | -543,500 | -100.0% | -1.35% | – |
| CBAY | Exit | CYMABAY THERAPEUTICS INC | $0 | – | -566,700 | -100.0% | -1.48% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CODEXIS INC | 39 | Q3 2023 | 10.9% |
| CHIMERIX INC | 31 | Q3 2022 | 16.4% |
| XOMA CORP DEL | 27 | Q3 2023 | 3.6% |
| FIBROGEN INC | 26 | Q1 2021 | 6.8% |
| BIOLINERX LTD (Does not reflect a reverse stock split effectuated after June 30, 2019) | 26 | Q1 2020 | 2.4% |
| OCULAR THERAPEUTIX INC | 24 | Q3 2023 | 17.6% |
| AXOGEN INC | 20 | Q4 2019 | 18.7% |
| ETON PHARMACEUTICALS INC | 20 | Q3 2023 | 5.6% |
| AMARIN CORP PLC | 20 | Q4 2020 | 6.6% |
| IMPRIMIS PHARMACEUTICALS INC | 19 | Q1 2020 | 5.9% |
View Opaleye Management Inc.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CHIMERIX INCSold out | February 13, 2023 | 0 | 0.0% |
| Larimar Therapeutics, Inc. | January 23, 2023 | 1,560,000 | 3.6% |
| TELA Bio, Inc. | June 10, 2022 | 1,557,500 | 10.7% |
| Gemini Therapeutics, Inc. /DESold out | February 01, 2022 | 0 | 0.0% |
| Adamas Pharmaceuticals IncSold out | January 26, 2022 | 0 | 0.0% |
| AVENUE THERAPEUTICS, INC. | February 12, 2021 | 9 | 11.0% |
| Cardiff Oncology, Inc. | February 12, 2021 | 9 | 11.0% |
| EDAP TMS SA | February 12, 2021 | 9 | 11.0% |
| Fortress Biotech, Inc. | February 12, 2021 | 9 | 11.0% |
| Gemini Therapeutics, Inc. /DE | February 12, 2021 | 9 | 11.0% |
View Opaleye Management Inc.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-24 |
| 4 | 2024-04-19 |
| SC 13G/A | 2024-04-09 |
| SC 13G | 2024-04-08 |
| 4 | 2024-03-28 |
| 4 | 2024-03-22 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13D/A | 2024-02-09 |
View Opaleye Management Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.